Martelli, N. A., and Usandivaras, G. (1977). Thorax, 32,[684][685][686][687][688][689][690]. Inhibition of aspirin-induced bronchoconstriction by sodium cromoglycate inhalation. Five patients with asthma and severe aspirin hypersensitivity were challenged on separate days with increasing doses of aspirin given by mouth, starting with 5 mg, until a reduction in FEV1 greater than 15 % was obtained. Sodium cromoglycate in doses of 20-40 mg inhibited the bronchoconstrictive reaction not only when inhaled before the challenge but also after it, at a time when progressive reduction in FEV1 values was taking place. According to these results, it seems reasonable to postulate sequential mast cell degranulation and liberation of mediators of anaphylaxis as the mechanism through which aspirin induces bronchoconstriction in aspirin-sensitive asthmatics. The differences between bronchial provocation tests and oral challenge with aspirin are stressed.
The syndrome of increased airways resistance in aspirin-sensitive asthmatics after aspirin ingestion (Samter and Beers, 1967 ) is characterised by the onset of watery rhinorrhoea followed within a few minutes by bronchoconstriction and wheezing. Symptoms may appear almost immediately after ingestion or be delayed up to two hours. This entity occurs especially in middle-aged women and is frequently associated with vasomotor rhinitis and nasal polyps. The same asthmatic attacks can be precipitated by a number of aspirin-like drugs: aminopyrine, indomethacin (Samter and Beers, 1968) , phenylbutazone, flufenamic acid, mephenamic acid (Szczeklik et al., 1975) , paracetamol, and dextropropoxyphene (Smith, 1971) . Although several hypotheses have been put forward, pathogenesis remains obscure.
This paper reports the effects of sodium cromoglycate (IntalR) on aspirin-induced bronchoconstriction in five patients with bronchial asthma.
Patients and methods
Five patients, four women aged 17, 42, 49, and 62 years and one man aged 57, were studied. All had bronchial asthma with a duration ranging from 2 to 17 (mean 9 4) years. All gave a history of severe asthmatic attacks after taking one tablet (500 mg) of aspirin. All reacted to prick tests with at least two inhalant allergens and had either blood eosinophilia of over 500/mm3 (0-5 x 109/l) or eosinophils in sputum or nasal secretions. Four had nasal polyps and three gave a history of family allergy. In one patient the first attack of asthma had coincided with taking an aspirin tablet, but in the rest hypersensitivity had developed after the onset of asthma. Although all patients had received steroids for brief periods, in no case was the control of asthma a serious problem. The patients were told that they would be given drugs which might induce severe bronchoconstriction but the kind of drug was unknown to them. Full consent was obtained from all patients.
Results
Oral ingestion of aspirin produced in all patients a reaction characterised by watery rhinorrhoea followed by audible wheezing and an asthma attack. Sometimes only the first symptom was present.
A fall in FEV1 greater than 15 % of control values was observed with doses of aspirin ranging from 20 to 100 mg. The time interval between ingestion of the drug and decrease in FEV1 ranged between 15 and 105 minutes. With increasing dosage there was a progressive shortening of this time interval, and FEV1 curves showed steeper slopes and lower values, indicating that the reaction was dose-dependent ( Fig. 1) . Once bronchoconstriction started there was a steady decline in FEV1, reaching its lowest value in 1-2 hours. This commonly took place between the second and the fourth hour after challenge and was followed in some patients by a very slow recovery phase, the FEV1 being 40 % under control values at 9 hours in one case and 20 % after 26 hours in another (Fig. 2) . The degree of fall in the FEV1 and the time relationship of the fall after challenge with a given dose of aspirin on successive days was found to be remarkably similar for each individual but different from case to case. (Davies, 1968) or bronchoconstriction due to repeated forced vital capacity manoeuvres duced neither rhinitis nor (Roncoroni et al., 1975 (Cox, 1971) . Since the im cromoglycate effectively principal action of sodium cromoglycate is to inhibit bronchoconstriction in allergic or, in certain circumstances, non-allergic ics whether administered mast cell degranulation, and since it affords proDnce there is considerable tection against aspirin-induced bronchoconstriction )gress. It would follow that in aspirin-sensitive asthmatics it seems reasonable to of action of sodium cromo-postulate that aspirin induces bronchoconstriction ie mechanism by which through mast cell degranulation and release of nstriction.
mediators of anaphylaxis. The question arises inhibits immediate-type whether this reaction is immunological (antibody to antigen (type I reaction mediated) or directly caused by the action of aspirin. nic IgE antibodies) both in Apart from occurring in asthmatics, its rather Altounyan, 1970). In man, explosive nature resembling an anaphylactic reaction um cromoglycate inhibits (when sufficient dose of aspirin is given), and its bronchoconstriction pro-inhibition by sodium cromoglycate, there are no enge with allergen. It also other reasons to indicate that this reaction is immunoig protection against in-logical (IgE mediated). On the other hand, there are lucing dual bronchocon-observations which support a non-immunological iate type I and late type III pathogenesis. Skin tests with aspirin in sensitive ion) or in some cases of patients are negative (Girard et al., 1969; Schlumpys and Hutchcroft, 1975). berger et al., 1974) . Serum IgE levels have been .s neither bronchodilating within normal limits, and efforts to transfer the properties (Cox and symptoms to monkeys with serum from aspirin s not antagonise the action sensitive patients and subsequent challenge with is (Cox, 1971) . It has been aspirin proved unsuccessful (Vatanasuk et al., 1971 ; prior inhalation of sodium Schlumberger et al., 1974) . tect against inhaled hista-A second point of interest is the substantial i) or prostaglandin (PG) difference between inhalation challenge and oral triction (Patel, 1975) . It has challenge with aspirin. In bronchial provocation tests a certain amount of antigen is delivered to the bronchial tree in a few breaths or minutes. The rapid interaction between antigen and mast cell bound IgE antibody causes bronchoconstriction which reaches its peak in approximately 15 minutes and subsides in two hours. When sodium cromoglycate is given after the challenge it affords little or no protection (Cox and Altounyan, 1970) because interaction between antigen and antibody has already occurred and degranulation of affected mast cells is probably completed. This reaction is dose dependent. On the other hand, aspirin has to be absorbed from the gut before reaching the lung via the circulation, and this delays the onset of the reaction which is also dose dependent. It has been shown that when aspirin is ingested in small doses (250 mg) the half-life of salicylate elimination is 2-9 hours (Levy, 1965 ). We have not been able to find reports about the pharmacokinetics of smaller doses of aspirin such as the ones we have given, but even assuming a shorter half-life there should be measurable levels of serum salicylate in our experiments at the end of the third or fourth hour. This results in a unique source of antigen continously challenging the lungs for some hours as opposed to the short exposure in inhalation challenge, and is reflected in the time-course of the reaction and probably in its response to sodium cromoglycate. Sodium cromoglycate is not effective when given after antigen inhalation. Furthermore, it does not work if the patient is wheezing and therefore should not be used in the treatment of acute asthma attacks (Kolotkyn et al., 1974) . Aspirin-induced bronchoconstriction seems to be an exception to the general rule and since sodium cromoglycate is effective after the challenge, mast cell degranulation in this case must proceed in a sequential fashion. It is possible, as has been suggested, that there may be different populations of mast cells (Beaven, 1976) , and it is conceivable that these cells might show differences in sensitivity to aspirin and this, coupled with sequential activation, could explain the prolonged time-course of the reaction and the inhibition of progressive bronchoconstriction by sodium cromoglycate. (Rowland et al., 1972) . On the other hand, the level ofsalicylic acid in plasma rises sharply and eventually exceeds that of aspirin to reach a plateau at 60 minutes, which lasts for three or more hours (Rowland etal., 1972; McDonald et al., 1972) . Since bronchoconstriction in procedure B appeared three or more hours after challenge, at a time when serum aspirin levels should be negligible, it seems highly unlikely that aspirin itself is the responsible antigen. On the other hand, serum salicylate levels during aspirin challenge are similar in patients with and without sensitivity to aspirin (McDonald et al., 1972) . Samter and Beers (1967) also failed to discover any difference in the handling of aspirin by various test systems between aspirinsensitive patients and normal controls. The same authors suggested that the cause ofaspirin intolerance lies in an alteration by pre-existing disease of peripheral chemoreceptors (kinin receptors) through which aspirin initiated a series of axon reflexes ending in an asthma attack. According to our findings this hypothesis seems untenable. Yurchak et al. (1970) suggested that aspirin might activate directly either complement components, with subsequent release of anaphylotoxins, or hypothetical tissue enzymes. In both situations there would be release of chemical mediators. No differences were found between levels of total haemolytic complement and components C4 and C3 in patients with aspirin sensitivity and normal controls (Delaney and Kay, 1976) This inhibition of PGE2 'disturbs the modulatory mechanism regulating bronchial tone, enhances the release of histamine from its stores, and enables broncho-constriction to take place' (Szczeklik and Czerniawska-Mysik, 1976) . These authors have shown that the ability of certain drugs to induce asthma attacks in aspirin-sensitive patients is roughly parallel to their power to inhibit prostaglandin biosynthesis in vitro (Szczeklik et al., 1975) . Perhaps it is the reduction of both PGE1 and PGF2a which is responsible for the syndrome because their low concentrations reduce cylic AMP levels and enhance mediator release (Kaliner and Austen, 1975) .
We feel that challenge with aspirin is a safe procedure, even in highly sensitised patients such as ours, provided that challenge is started with doses of 5 to 10 mg under close medical supervision. It must be borne in mind that aspirin hypersensitivity in these patients is not the cause of the disease because in most of them respiratory symptoms precede the onset of intolerance to aspirin, and careful avoidance of offending drugs does not alter the natural course of the disease (Samter and Beers, 1967) . It is not surprising then that sodium cromoglycate did not have a therapeutic effect in a double-blind crossover study in patients with asthma and aspirin hypersensitivity (Gwin et al., 1974) . Nevertheless there would seem to be a place for it after the start of an asthmatic attack due to aspirin or, if the patient realised that he had taken a dose of aspirin by mistake, sodium cromoglycate could be used in a prophylactic fashion. 
